Dr Reddy’s Laboratories SA, a subsidiary of Dr Reddy’s Laboratories, has signed a development and licence agreement with Coya Therapeutics Inc for the development and commercialisation of COYA 302, a combination biologic therapy for ALS. Dr Reddy’s will have an exclusive licence to commercialise COYA 302 in the US, Canada, EU, and UK, while Coya will have the right to commercialise it in Japan, Mexico, and South American countries. COYA 302 suppresses chronic inflammation caused by neurodegenerative diseases. Dr Reddy’s will make upfront and milestone payments to Coya.
Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News